SMALL CELL LUNG CANCER ( SCLC )

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in everyday medical practice. Researchers will track 500 patients to see side effects, survival time, and how long the cancer stays under control. The goal i…

This early-stage trial tests the safety and best dose of a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to find the highest safe dose and check for side effects. Participants mus…

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…

This study tests a new drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 102 people will take part in this early-phase trial.

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3, found on small cell lung cancer and other solid tumors. About 138 adults whose cancer has returned after standard treatments will receive the drug to see if it is safe and shr…

This study tests an experimental oral drug called VMD-928, given alone or with pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 242 peop…

This study tests a new medicine (PF-08634404) given with chemotherapy for adults with transformed small cell lung cancer, a rare and aggressive cancer that develops after other treatments stop working. About 40 participants who have not yet been treated for this cancer type will …

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery can help keep small cell lung cancer from coming back. About 65 adults who had their lung cancer completely removed will receive this combination. The goal is to see if this …

This early-phase trial tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to attack cancer cells carrying a protein calle…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread widely. About 550 participants will receive the drug combo or a standard treatment to see which works better…

This study tests a new treatment for adults with small cell lung cancer that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-NK cells) designed to recognize and attack cancer cells. The goal is to find the safest dose …

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…

This early-phase study tests a new drug called IBI115, alone or with other treatments, in 150 adults with advanced small cell lung cancer. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurable cancer and b…

This study tests an experimental drug called CP-383 in 150 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that haven't responded to standard treatments. Participants take the drug daily to see if it slows cancer growth and to find the best dose. The go…

This study tests a new drug, Peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The goal is to find safe doses and see if the drug works alone or with chemotherapy. About 203 participants will take part in this early-phase trial.

This early-stage study tests a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and attack cancer cells. About 30 adults with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments will receive the d…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment …

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This study is testing a new radioactive probe called PFD3 to see if it can improve the detection and assessment of small cell lung cancer (SCLC) using PET/CT scans. About 30 adults with SCLC will receive the probe and be monitored for side effects and imaging accuracy. The goal i…

This study is observing 240 lung cancer patients in Germany and Austria who are receiving the drug tislelizumab as part of their normal care. Researchers want to see how long patients live, how they feel, and what side effects occur. The goal is to learn how well the drug works o…

This study is gathering detailed information from 500 people with small cell lung cancer to learn how to tailor treatments like radiation and immunotherapy to each patient. The goal is to find the best timing and doses of radiotherapy to work with immunotherapy, improving outcome…